- Lantheus Holdings, Inc. (NASDAQ:LNTH) boasts a Return on Invested Capital (ROIC) of 17.16% and a Weighted Average Cost of Capital (WACC) of 4.55%, indicating efficient capital utilization and profitability.
- Compared to its peers, Lantheus shows superior financial performance with a ROIC to WACC ratio of 3.77, suggesting it is generating returns well above its cost of capital.
- Medpace Holdings, Inc. stands out within the sector with an exceptional ROIC of 114.80% and a WACC of 10.46%, leading to a ROIC to WACC ratio of 10.98, indicating superior capital efficiency and growth potential.
Lantheus Holdings, Inc. (NASDAQ:LNTH) is a company that specializes in the development and commercialization of innovative diagnostic imaging agents and products. These products are primarily used in the diagnosis and treatment of cardiovascular and other diseases. Lantheus competes with other companies in the medical and pharmaceutical sectors, such as ShockWave Medical, Inc., Medpace Holdings, Inc., LivaNova PLC, Apellis Pharmaceuticals, Inc., and Natera, Inc.
Lantheus Holdings boasts a Return on Invested Capital (ROIC) of 17.16% and a Weighted Average Cost of Capital (WACC) of 4.55%. This results in a ROIC to WACC ratio of 3.77, indicating that the company is generating returns well above its cost of capital. This is a positive indicator for investors, as it suggests efficient capital utilization and profitability.
In comparison, ShockWave Medical, Inc. has a ROIC of 5.29% and a WACC of 8.26%, resulting in a ROIC to WACC ratio of 0.64. This suggests that ShockWave is not generating returns above its cost of capital, which may be a concern for investors. On the other hand, Medpace Holdings, Inc. stands out with a ROIC of 114.80% and a WACC of 10.46%, leading to a ROIC to WACC ratio of 10.98. This indicates exceptional efficiency in generating returns, making Medpace an attractive investment opportunity.
LivaNova PLC has a ROIC of 11.60% and a WACC of 7.90%, resulting in a ROIC to WACC ratio of 1.47. While this is above 1, it is not as high as Lantheus or Medpace, suggesting moderate efficiency in capital utilization. Apellis Pharmaceuticals, Inc. and Natera, Inc. both have negative ROIC to WACC ratios of -4.02 and -1.30, respectively. This indicates that these companies are not generating returns above their cost of capital, which may be a red flag for potential investors.
Overall, Lantheus Holdings, Inc. demonstrates strong performance with its ROIC to WACC ratio of 3.77, indicating efficient capital utilization. However, Medpace Holdings, Inc. leads the peer group with a significantly higher ratio, suggesting superior capital efficiency and growth potential. Investors may consider these metrics when evaluating investment opportunities within this sector.
